MA31535B1 - (oxazolidinon-5-yl-méthyl)-2-thiophène-carboxamides substitués et leur utilisation dans le domaine de la coagulation sanguine - Google Patents

(oxazolidinon-5-yl-méthyl)-2-thiophène-carboxamides substitués et leur utilisation dans le domaine de la coagulation sanguine

Info

Publication number
MA31535B1
MA31535B1 MA32539A MA32539A MA31535B1 MA 31535 B1 MA31535 B1 MA 31535B1 MA 32539 A MA32539 A MA 32539A MA 32539 A MA32539 A MA 32539A MA 31535 B1 MA31535 B1 MA 31535B1
Authority
MA
Morocco
Prior art keywords
thiophener
oxazolidinon
carboxamides
substituted
methyl
Prior art date
Application number
MA32539A
Other languages
English (en)
Inventor
Swen Allerheiligen
Marcus Bauser
Dirk Heimbach
Stefan Heitmeier
Mark Jean Gnoth
Christoph Gerdes
Degenfeld Georges Von
Susanne Roehrig
Ulrich Rester
Elke Dittrich-Wengenroth
Uwe Saatmann
Adrian Tersteegen
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39731148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31535(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MA31535B1 publication Critical patent/MA31535B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

L'INVENTION CONCERNE DE NOUVELLES OXAZOLIDINONES SUBSTITUÉES, DES PROCÉDÉS POUR LEUR PRODUCTION, LEUR UTILISATION POUR LE TRAITEMENT ET/OU LA PROPHYLAXIE DE MALADIES, AINSI QUE LEUR UTILISATION POUR PRODUIRE DES MÉDICAMENTS SERVANT AU TRAITEMENT ET/OU À LA PROPHYLAXIE DE MALADIES, NOTAMMENT DE MALADIES THROMBOEMBOLIQUES.
MA32539A 2007-06-20 2010-01-19 (oxazolidinon-5-yl-méthyl)-2-thiophène-carboxamides substitués et leur utilisation dans le domaine de la coagulation sanguine MA31535B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007028319A DE102007028319A1 (de) 2007-06-20 2007-06-20 Substituierte Oxazolidinone und ihre Verwendung

Publications (1)

Publication Number Publication Date
MA31535B1 true MA31535B1 (fr) 2010-07-01

Family

ID=39731148

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32539A MA31535B1 (fr) 2007-06-20 2010-01-19 (oxazolidinon-5-yl-méthyl)-2-thiophène-carboxamides substitués et leur utilisation dans le domaine de la coagulation sanguine

Country Status (42)

Country Link
US (2) US8383822B2 (fr)
EP (1) EP2170877B1 (fr)
JP (1) JP5537421B2 (fr)
KR (1) KR101535312B1 (fr)
CN (1) CN101821259B (fr)
AR (2) AR066981A1 (fr)
AU (1) AU2008266525B8 (fr)
BR (1) BRPI0813736A2 (fr)
CA (1) CA2692166C (fr)
CL (1) CL2008001691A1 (fr)
CO (1) CO6251281A2 (fr)
CR (1) CR11168A (fr)
CU (1) CU23820A3 (fr)
CY (1) CY1113580T1 (fr)
DE (1) DE102007028319A1 (fr)
DK (1) DK2170877T5 (fr)
DO (1) DOP2009000285A (fr)
EC (1) ECSP099807A (fr)
ES (1) ES2397799T3 (fr)
GT (1) GT200900319A (fr)
HN (1) HN2009003424A (fr)
HR (1) HRP20130072T1 (fr)
IL (1) IL202351A (fr)
JO (1) JO2798B1 (fr)
MA (1) MA31535B1 (fr)
MX (1) MX2009013711A (fr)
MY (1) MY150931A (fr)
NZ (1) NZ581540A (fr)
PA (1) PA8784301A1 (fr)
PE (1) PE20090332A1 (fr)
PL (1) PL2170877T3 (fr)
PT (1) PT2170877E (fr)
RS (1) RS52639B (fr)
RU (1) RU2481345C2 (fr)
SG (1) SG182220A1 (fr)
SI (1) SI2170877T1 (fr)
SV (1) SV2009003435A (fr)
TN (1) TN2009000503A1 (fr)
TW (1) TWI413642B (fr)
UA (1) UA98793C2 (fr)
UY (1) UY31133A1 (fr)
WO (1) WO2008155032A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
DE102007028319A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102010028362A1 (de) 2010-04-29 2011-11-03 Bayer Schering Pharma Aktiengesellschaft Herstellverfahren
CN102464658B (zh) * 2010-11-03 2014-04-16 天津药物研究院 噁唑烷酮衍生物及其制备方法和用途
CA2824885A1 (fr) 2011-01-19 2012-07-26 Bayer Intellectual Property Gmbh Proteines de liaison a des inhibiteurs de facteurs de coagulation
CN103626749A (zh) * 2012-08-21 2014-03-12 苏州泽璟生物制药有限公司 取代的噁唑烷酮化合物和包含该化合物的药物组合物及其用途
CN103232446B (zh) * 2013-05-17 2015-09-23 天津药物研究院 一种噁唑烷酮衍生物晶型ⅱ及其制备方法和用途
WO2014183667A1 (fr) * 2013-05-17 2014-11-20 天津药物研究院 Solvate d'acide acétique de dérivé d'oxazolidinone, procédé de préparation dudit solvate, et application associée
CN103242307B (zh) * 2013-05-17 2015-08-12 天津药物研究院有限公司 一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
DE4319041A1 (de) 1992-10-23 1994-04-28 Bayer Ag Trisubstituierte Biphenyle
ATE431347T1 (de) 1996-10-14 2009-05-15 Bayer Healthcare Ag Neue heterocyclylmethyl-substituierte pyrazolderivate und ihre verwendung in der behandlung von herz-kreislauf-erkrankungen
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
DE19649460A1 (de) 1996-11-26 1998-05-28 Bayer Ag Neue substituierte Pyrazolderivate
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
WO2000024227A1 (fr) 1998-10-16 2000-04-27 Medical Solutions, Inc. Systeme et procede de regulation de temperature pour le chauffage et le maintien d'articles medicaux a des temperatures voulues
DE19920352A1 (de) 1999-05-04 2000-11-09 Bayer Ag Substituiertes Pyrazolderivat
CA2375920A1 (fr) 1999-06-14 2000-12-21 Eli Lilly And Company Composes
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
SK7572002A3 (en) * 1999-12-21 2002-12-03 Upjohn Co Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114005D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
TWI257389B (en) 2001-06-12 2006-07-01 Lilly Co Eli Pharmaceutical compound
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
WO2003000657A1 (fr) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Derives de diamine
JP2005520782A (ja) * 2001-07-12 2005-07-14 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 向上した水溶解度を有するアミド含有化合物およびアミド含有化合物の水溶解度を向上させる方法
AU2002341693B2 (en) 2001-09-21 2008-05-29 Bristol-Myers Squibb Holdings Ireland Unlimited Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
TW200303201A (en) 2001-12-10 2003-09-01 Bristol Myers Squibb Co Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
PE20040804A1 (es) 2002-12-19 2004-12-31 Boehringer Ingelheim Pharma DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa
US7205318B2 (en) 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
DE10322469A1 (de) 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclische Verbindungen
US7265140B2 (en) * 2003-09-23 2007-09-04 Pfizer Inc Acyloxymethylcarbamate prodrugs of oxazolidinones
KR101215153B1 (ko) 2003-11-12 2012-12-24 다이이찌 산쿄 가부시키가이샤 티아졸 유도체의 제조법
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
JP2005179272A (ja) 2003-12-19 2005-07-07 Yamanouchi Pharmaceut Co Ltd カルボキサミド誘導体のマロン酸塩結晶
DE102004002044A1 (de) * 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
GB0405272D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
KR101195801B1 (ko) 2004-06-18 2012-11-05 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｘａ 인자 억제제
US20060069260A1 (en) * 2004-09-28 2006-03-30 Huiping Zhang Preparation of N-aryl pyridones
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
WO2006106804A1 (fr) 2005-03-31 2006-10-12 Mochida Pharmaceutical Co., Ltd. Composé spiro tricyclique comprenant un groupement acyle lié à un atome d'azote de cycle
WO2007008142A1 (fr) 2005-07-08 2007-01-18 Astrazeneca Ab Dérivés de sulfonamides hétérocycliques en tant qu'inhibiteurs du facteur xa
AR057976A1 (es) * 2005-08-29 2008-01-09 Boehringer Ingelheim Int Biarilos sustituidos y su uso como medicamentos.
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005050497A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Difluorphenol-Derivate und ihre Verwendung
DE102005050498A1 (de) 2005-10-21 2007-06-06 Bayer Healthcare Aktiengesellschaft Cyclopropylessigsäure-Derivate und ihre Verwendung
DE102005050375A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Tetrazol-Derivate und ihre Verwendung
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
DE102005050376A1 (de) 2005-10-21 2007-05-31 Bayer Healthcare Ag Dicarbonsäure-Derivate und ihre Verwendung
DE102006025314A1 (de) * 2006-05-31 2007-12-06 Bayer Healthcare Ag Arylsubstituierte Heterozyklen und ihre Verwendung
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
DE102007028407A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028406A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung

Also Published As

Publication number Publication date
DK2170877T3 (da) 2013-02-11
HK1147991A1 (en) 2011-08-26
US8383822B2 (en) 2013-02-26
UA98793C2 (ru) 2012-06-25
HN2009003424A (es) 2012-01-05
DE102007028319A1 (de) 2008-12-24
IL202351A0 (en) 2010-06-30
ECSP099807A (es) 2010-01-29
MX2009013711A (es) 2010-02-01
AU2008266525B2 (en) 2013-09-05
JO2798B1 (en) 2014-03-15
ES2397799T3 (es) 2013-03-11
RS52639B (sr) 2013-06-28
CO6251281A2 (es) 2011-02-21
PA8784301A1 (es) 2009-02-09
TN2009000503A1 (en) 2011-03-31
US20140057951A1 (en) 2014-02-27
IL202351A (en) 2015-10-29
UY31133A1 (es) 2009-01-30
AR066981A1 (es) 2009-09-23
EP2170877B1 (fr) 2012-11-21
RU2481345C2 (ru) 2013-05-10
WO2008155032A1 (fr) 2008-12-24
KR20100021615A (ko) 2010-02-25
SV2009003435A (es) 2010-08-23
TW200911797A (en) 2009-03-16
DOP2009000285A (es) 2010-01-31
BRPI0813736A2 (pt) 2014-12-30
PE20090332A1 (es) 2009-04-09
CU23820A3 (es) 2012-06-21
CA2692166C (fr) 2015-01-27
CA2692166A1 (fr) 2008-12-24
KR101535312B1 (ko) 2015-07-09
GT200900319A (es) 2011-11-09
RU2010101307A (ru) 2011-07-27
CN101821259B (zh) 2013-10-30
CN101821259A (zh) 2010-09-01
CU20090216A7 (es) 2011-10-14
CR11168A (es) 2010-06-28
CY1113580T1 (el) 2016-06-22
AU2008266525B8 (en) 2013-09-19
JP2010530383A (ja) 2010-09-09
NZ581540A (en) 2012-01-12
SI2170877T1 (sl) 2013-03-29
US20100184740A1 (en) 2010-07-22
JP5537421B2 (ja) 2014-07-02
SG182220A1 (en) 2012-07-30
AU2008266525A1 (en) 2008-12-24
EP2170877A1 (fr) 2010-04-07
AR067057A1 (es) 2009-09-30
TWI413642B (zh) 2013-11-01
PL2170877T3 (pl) 2013-03-29
DK2170877T5 (da) 2013-03-04
MY150931A (en) 2014-03-14
HRP20130072T1 (hr) 2013-02-28
US8846934B2 (en) 2014-09-30
CL2008001691A1 (es) 2008-12-26
PT2170877E (pt) 2013-01-28

Similar Documents

Publication Publication Date Title
MA31570B1 (fr) Oxazolidinones substitués et leur utilisation
MA34721B1 (fr) Acides carboxyliques 1-benzylcycloalkyle substitués et leur utilisation
MA31920B1 (fr) 4-(4-cyano-2-thioaryle)-dihydropyrimidinone et son utilisation
MA42376A (fr) Dérivés d'oxopyridine substitués
MA35365B1 (fr) Pyrimidines annelées substituées et leur utilisation
MA34248B1 (fr) 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA32226B1 (fr) Compositions et leurs procedes de preparation et d'utilisation
ATE537168T1 (de) Substituierte oxazolidinone und ihre verwendung
MA46018A (fr) Activateurs d'édition du génome
MA35844B1 (fr) Pyrimidines et triazines annelées substituées et leur utilisation
EP2844636A4 (fr) Procédés pour le traitement de la rétinopathie diabétique et d'autres maladies ophtalmiques
MA31167B1 (fr) Inhibiteurs de l'activite de akt
ATE397930T1 (de) Verwendung von oxazolidinon-chinolin-hybrid- antibiotika zur behandlung von anthrax und anderen infektionen
JO2798B1 (en) (Oxazolidinone-5-yl-methyl) -2-Thiophene-carboxamides substituted and used in blood clotting
EP2210092A4 (fr) Compositions comprenant des sémaphorines pour le traitement de maladies associées à l'angiogenèse et leurs procédés de sélection
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MA38925A1 (fr) Dérivés de phénylalanine substitués
MA33753B1 (fr) Nouveaux camphènes arylés, procédés de préparation et utilisations de ceux-ci
MA33290B1 (fr) Pipéridines substituées
WO2019016597A3 (fr) Protéines synthétiques et leurs utilisations thérapeutiques
MA31902B1 (fr) Oxazolidinones pour le traitement et/ou la prophylaxie de l'insuffisance cardiaque
MA33291B1 (fr) Pipéridines substituées
DE502007006625D1 (de) 3-cyano-5-thiazaheteroaryl-dihydropyridine und ihrnkungen
ZA200908583B (en) Substituted (oxazolidinon-5-yl-methyl)-2-thiophene-carboxamides and use thereof in the field of blood coagulation